Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them
The oligonucleotide derivative of the present invention is represented by Formula (1). This derivative is considered to be introduced into cells by binding of its amino sugar chain moiety to a ligand on cell surfaces, and have selective drug delivery function. The oligonucleotide derivative can be easily synthesized and introduced into cells without using a lipofection reagent. wherein A and B are independently modified or unmodified oligonucleotides whose total chain length is 3 or more, and A and B do not contain hydroxyl groups at 3′ and 5′ ends of the oligonucleotide; S represents a sugar substituent, a peptide chain, or a tocopherol-binding group; and an alkyl group may be bound instead of hydrogen bound to a benzene ring.
1. An oligonucleotide derivative represented by the following formula (1): (wherein R 1 and R 2 each independently represent hydrogen or a phosphate group; a, b, and c are independently integers of 0 or more, and at least one of them is 1 or more; A and B are independently modified or unmodified oligonucleotides whose combined chain length is 3 or more, and A and B do not contain hydroxyl groups at 3′ and 5′ ends of the oligonucleotide; and S 1 is a substituent represented by the following (α)):
2. The oligonucleotide derivative according to claim 1 , wherein the modified or unmodified oligonucleotides have a partial structure —(CH 2 )n-, where n is a natural number of 1 or greater.
3. The oligonucleotide derivative according to claim 1 , wherein R 1 and R 2 are H.
4. The oligonucleotide derivative according to claim 1 , wherein b is 0.
5. The oligonucleotide derivative according to claim 1 , wherein a and b are both 0.
6. The oligonucleotide derivative according to claim 1 , wherein c is 1 or more and 5 or less.
7. The oligonucleotide derivative according to claim 1 , wherein the combined chain length of A and B is 10 or more and 35 or less.
8. The oligonucleotide derivative according to claim 1 , wherein A and B are oligoribonucleotides.
9. An oligonucleotide construct for regulating gene expression, comprising the oligonucleotide derivative according to claim 1 ,
wherein the construct is selected from single- and double-stranded DNAs, single- and double-stranded RNAs, DNA/RNA chimeras, and DNA/RNA hybrids.
10. The construct according to claim 9 , being selected from anti-genes, antisenses, aptamers, siRNAs, miRNAs, shRNAs, and ribozymes.
11. The construct according to claim 9 , which has a unit represented by the following formula (4) or (5) at a dangling end (wherein S 1 is a substituent represented by the following (α), letters “LINKER” surrounded by a rectangular frame represent a linker, S 2 is a substituent represented by the following (β), (γ), (δ), or (ε) bound to an end of the linker (two or more S 2 s may be bound to the linker), and n represents a natural number of 0 to 4),
or a peptide chain (ε) having an amino acid sequence of RGD at its end.
12. The construct according to claim 11 , being a siRNA wherein in the oligonucleotide derivative, a and b are 0, c is 1 or 2, and a unit represented by the following formula (4) or (5) is contained at a 3′ dangling end (wherein S 1 is a substituent represented by the following (α), letters “LINKER” surrounded by a rectangular frame represent a linker, S 2 is a substituent represented by the following (β), (γ), (δ), or (ε) bound to an end of the linker (two or more S 2 s may be bound to the linker), and n represents a natural number of 0 to 4),
or a peptide chain (ε) having an amino acid sequence of RGD at its end.
13. An oligonucleotide derivative represented by the following formula (2): (wherein R 1 and R 2 each independently represent hydrogen or a phosphate group; a, b, and c are independently integers of 0 or more, and at least one of them is 1 or more; A and B are independently modified or unmodified oligonucleotides whose combined chain length is 3 or more, and A and B do not contain hydroxyl groups at 3′ and 5′ ends of the oligonucleotide; letters “LINKER” surrounded by a rectangular frame represent a linker; S 2 is a substituent represented by the following (β), (γ), (δ), or (ε) bound to an end of the linker (two or more S 2 s may be bound to the linker); and n represents a natural number of 0 to 4:
or a peptide chain (ε) having an amino acid sequence of RGD at its end.
14. The oligonucleotide derivative according to claim 13 , wherein the modified or unmodified oligonucleotides have a partial structure —(CH 2 )n-, where n is a natural number of 1 or greater.
15. The oligonucleotide derivative according to claim 13 , wherein R 1 and R 2 are H.
16. The oligonucleotide derivative according to claim 13 , wherein b is 0.
17. The oligonucleotide derivative according to claim 13 , wherein a and b are both 0.
18. The oligonucleotide derivative according to claim 13 , wherein c is 1 or more and 5 or less.
19. The oligonucleotide derivative according to claim 13 , wherein the combined chain length of A and B is 10 or more and 35 or less.
20. The oligonucleotide derivative according to claim 13 , wherein A and B are oligoribonucleotides.
21. An oligonucleotide construct for regulating gene expression, comprising the oligonucleotide derivative according to claim 13 ,
wherein the construct is selected from single- and double-stranded DNAs, single- and double-stranded RNAs, DNA/RNA chimeras, and DNA/RNA hybrids.
22. The construct according to claim 21 , being selected from anti-genes, antisenses, aptamers, siRNAs, miRNAs, shRNAs, and ribozymes.
23. The construct according to claim 21 , which has a unit represented by the following formula (4) or (5) at a dangling end (wherein S 1 is a substituent represented by the following (α), letters “LINKER” surrounded by a rectangular frame represent a linker, S 2 is a substituent represented by the following (β), (γ), (δ), or (ε) bound to an end of the linker (two or more S 2 s may be bound to the linker), and n represents a natural number of 0 to 4),
or a peptide chain (ε) having an amino acid sequence of RGD at its end.
24. The construct according to claim 23 , being a siRNA wherein in the oligonucleotide derivative, a and b are 0, c is 1 or 2, and a unit represented by the following formula (4) or (5) is contained at a 3′ dangling end (wherein S 1 is a substituent represented by the following (α), letters “LINKER” surrounded by a rectangular frame represent a linker, S 2 is a substituent represented by the following (β), (γ), (δ), or (ε) bound to an end of the linker (two or more S 2 s may be bound to the linker), and n represents a natural number of 0 to 4),
or a peptide chain (ε) having an amino acid sequence of RGD at its end.
25. A method for producing an oligonucleotide derivative, comprising performing a click reaction of compound (6) or (7) with an oligonucleotide having an ethynyl group to produce an oligonucleotide derivative comprising at least one unit represented by the following formula (4) or (5) (wherein S 1 is a substituent represented by the following (α), letters “LINKER” surrounded by a rectangular frame represent a linker, S 2 is a substituent represented by the following (β), (γ), (δ), or (ε) bound to an end of the linker (two or more S 2 s may be bound to the linker), and n represents a natural number of 0 to 4),
or a peptide chain (ε) having an amino acid sequence of RGD at its end.